CORRESP Filing
Nuo Therapeutics, Inc.
Date: May 8, 2025 · CIK: 0001091596 · Accession: 0001437749-25-015587
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286912
Letter
aurx20250508_corresp.htm
8285 El Rio, Suite 190
Houston, TX 77054
Phone 346.396.4770
May 9, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Jane Park
Re: Request for Acceleration of Effectiveness of
Registration Statement on Form S-3 as amended (File No. 333-286912)
Ladies and Gentlemen,
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nuo Therapeutics, Inc. hereby respectfully requests that the effective time of the above referenced Registration Statement be accelerated to 4:00 p.m., Eastern Time, on Monday, May 12, 2025, or as soon thereafter as practicable.
Please contact David T. Mittelman of Lucendo LLP at (415) 854-0453 to confirm once the above referenced Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Very truly yours,
Nuo Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm aurx20250508_corresp.htm 8285 El Rio, Suite 190 Houston, TX 77054 Phone 346.396.4770 May 9, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Jane Park Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-3 as amended (File No. 333-286912) Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nuo Therapeutics, Inc. hereby respectfully requests that the effective time of the above referenced Registration Statement be accelerated to 4:00 p.m., Eastern Time, on Monday, May 12, 2025, or as soon thereafter as practicable. Please contact David T. Mittelman of Lucendo LLP at (415) 854-0453 to confirm once the above referenced Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter. Very truly yours, Nuo Therapeutics, Inc. By: /s/ David E. Jorden David E. Jorden Chief Executive and Financial Officer cc: David T. Mittelman, Esq. Lucendo LLP